Global Market Report for Electronic Nicotine Delivery Systems (ENDS)

Aug.16.2022
Global Market Report for Electronic Nicotine Delivery Systems (ENDS)
The global market for electronic nicotine delivery systems, including e-cigarettes, is predicted to grow rapidly through 2026.

The Business Research Company has released a market research report that predicts the size and trends of the global market for electronic nicotine delivery systems, including e-cigarettes, from 2022 to 2026.


According to a global market report by a business research company, the vaporizer, electronic cigarette, and other electronic nicotine delivery systems (ENDS) market is expected to grow from $19.92 billion in 2021 to $25.03 billion in 2022, with a compound annual growth rate (CAGR) of 25.6%. The market growth is mainly due to companies resuming operations and adapting to a new normal, while recovering from the impact of COVID-19, which earlier resulted in restrictive measures including social distancing, remote work, and the closure of commercial activities, posing operational challenges. The vaporizer, electronic cigarette, and other ENDS market is expected to reach $55.99 billion in 2026, with a CAGR of 22.3%. The awareness of health issues caused by traditional cigarettes among smokers is driving the growth of the electronic cigarette market.


The main trends in the market for vaporizers, electronic cigarettes, and other electronic nicotine delivery systems (ENDS) are as follows: There is an increasing demand for medicinal cannabis vaporizers in the vaporizer market. Cannabis vaporizers have controlled heating technology and can precisely adjust heating temperature through the display screen on the device, allowing users to fully control the density of the aerosol produced. The TBRC's 2022 Global Market Report on Vaporizers, Electronic Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS) includes the following information:


This report categorizes the market based on geographical regions including the Asia Pacific, China, Western Europe, Eastern Europe, North America, the United States, South America, the Middle East, and Africa. It also reflects segmentation by country, including Australia, Brazil, mainland China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom, and the United States, as well as by product type, including atomizers, e-cigarettes, and other electronic nicotine delivery systems. Within these product categories, e-cigarettes can be further divided into disposable, rechargeable, and modular types, while atomizers include e-cigarette atomizers, cannabis atomizers, and medical atomizers. The global market for e-cigarettes and other ENDS can be segmented geographically into North America, South America, the Asia Pacific, Eastern Europe, Western Europe, the Middle East, and Africa. The APAC region holds the largest market share. Leading market players mentioned in the report include Dash Vapes, Hubbly Bubbly, Liquideu, Nice Vapor, Pacific Smoke International, Puff Ecig, Simple Vape Co. London Ltd, Smokio, Vape Escapes, and Vapor Line. The report also highlights current trends, opportunities, strategies, and more. Disclaimer:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness or accuracy of the content. The compilation of this article is only intended for industry exchanges and research purposes.


Due to the limitations of the translation skills, the translated article may not fully express the original meaning. Please refer to the original text for accuracy.


In terms of any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions and positions, 2FIRSTS is fully aligned with the Chinese government.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
UAE Sets Dh1-Per-ml Minimum Excise Price for Vape Liquids From Sept. 1 While Keeping 100% Tax Rate
UAE Sets Dh1-Per-ml Minimum Excise Price for Vape Liquids From Sept. 1 While Keeping 100% Tax Rate
The UAE Ministry of Finance will introduce a minimum excise price for e-liquids used in vaping and electronic smoking devices from September 1, 2026. The minimum excise price will be set at AED 1 per millilitre. The existing 100% excise tax rate will continue to apply to tobacco and electronic smoking products. The measure changes the minimum taxable base rather than the tax rate, with the UAE government saying it aims to establish unified tax standards, improve market compliance and prevent pricing loopholes.
Regulations
Aug.07 by 2Firsts Perspectives
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26